Haemonetics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Haemonetics stock has a consensus rating of "Buy" and an average price target of $81.6. The average 1-year stock price forecast is 4.35% higher than the current stock price, while the lowest is $62 (-20.72%) and the highest is $104 (+32.99%).

Price Target: $81.6 (+4.35%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$62	$81.6	$82	$104
Change	-20.72%	+4.35%	+4.86%	+32.99%

Analyst Ratings

The average analyst rating for Haemonetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	4
Buy	4	4	4	4	4	4
Hold	4	4	4	4	4	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joanne Wuensch Citi	Citi	Hold Maintains $64 → $70	Hold	Maintains	$64 → $70	-10.49%	May 28, 2026
Travis Steed Bank of America Securities	Bank of America Securities	Buy Upgrades $72 → $80	Buy	Upgrades	$72 → $80	+2.30%	May 22, 2026
Michael Petusky Barrington	Barrington	Buy Maintains $94 → $89	Buy	Maintains	$94 → $89	+13.81%	May 12, 2026
David Rescott Robert W. Baird	Robert W. Baird	Buy Maintains $72 → $67	Buy	Maintains	$72 → $67	-14.32%	May 8, 2026
Rohin K Patel J.P. Morgan	J.P. Morgan	Hold Reiterates $74 → $62	Hold	Reiterates	$74 → $62	-20.72%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

1.40B

from 1.33B

4.98%

from 1.33B

Revenue Next Year

1.47B

from 1.40B

5.27%

from 1.40B

EPS This Year

5.22

from 4.96

5.23%

from 4.96

EPS Next Year

5.76

from 5.22

10.34%

from 5.22

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Apr 2, 2022	Apr 1, 2023	Mar 30, 2024	Mar 29, 2025	Mar 28, 2026	Mar 31, 2027
Revenue	993.20M	1.17B	1.31B	1.36B	1.33B	1.40B
Revenue Growth	14.10%	17.67%	12.01%	3.96%	-1.97%	4.98%
Gross Profit	530.77M	622.87M	708.57M	778.55M	792.87M	849.19M
Gross Margin	53.44%	53.30%	54.13%	57.21%	59.43%	60.64%
Operating Income	105.17M	167.20M	205.49M	247.10M	251.53M	364.20M
Net Income	43.38M	115.40M	117.56M	167.68M	97.31M	173.20M
EPS	-	-	-	-	4.96	5.22
EPS Growth	-	-	-	-	8.53%	5.23%
Forward PE	23.82	25.45	20.49	13.21	10.46	14.98
Free Cash Flow	88.90M	50.09M	148.53M	183.89M	298.09M	287.00M
No. Analysts	-	-	-	-	-	11

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2027	2028	2029
High	1.4B
Avg	1.4B
Low	1.4B

Revenue Growth

Revenue Growth	2027	2028	2029
High	5.5%
Avg	5.0%
Low	4.1%

EPS Forecast

EPS	2027	2028	2029
High	5.26
Avg	5.22
Low	5.17

EPS Growth

EPS Growth	2027	2028	2029
High	6.0%
Avg	5.2%
Low	4.2%